Literature DB >> 21726928

Replacing GnRH agonists with GnRH antagonists in oocyte recipient cycle did not adversely affect the pregnancy rates.

Francisca Martínez1, Laura Latre, Elisabet Clua, Ignacio Rodriguez, Buenaventura Coroleu.   

Abstract

UNLABELLED: The synchronization of the donor stimulation with the endometrial preparation of the recipient is usually done by downregulating the recipient's pituitary with a GnRH analog.
OBJECTIVE: The aim of this study is to compare pregnancy and implantation rates among premenopausal oocyte recipients synchronized by pituitary suppression with GnRH agonist (Group AGO) or antagonist (Group ANTAG) and standard endometrial preparation with estrogen and gestagen. STUDY
DESIGN: Prospective, observational, transversal, comparative study. Consecutive recipients treated at Institut Universitari Dexeus between July 2008 and December 2009.
RESULTS: One hundred and eighty-three premenopausal women were included. No differences were found regarding the age of donors nor the age of recipients, fertilization rates, number of embryos transferred and embryo quality. No differences were found in clinical pregnancy rates (56.1% Group AGO vs. 52.4% Group ANTAG).
CONCLUSION: The administration of GnRH antagonists during endometrial preparation in oocyte recipients facilitates synchronization without affecting the pregnancy rate.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21726928     DOI: 10.1016/j.ejogrb.2011.06.013

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  1 in total

1.  Assessing the optimal dose for Cetrorelix in Chinese women undergoing ovarian stimulation during the course of IVF-ET treatment.

Authors:  Qiaohong Lai; Jun Hu; Dan Zeng; Juan Hu; Fuying Cai; Fei Yang; Cai Chen; Xiaoyu He; Ping Yang; Qilin Yu; Shu Zhang; Jun-Fa Xu; Cong-Yi Wang
Journal:  Am J Transl Res       Date:  2013-12-01       Impact factor: 4.060

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.